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Dissecting the roles of Raf- and PI3K-signalling pathways in
melanoma formation and progression in a zebrafish model
Abstract
Deregulated Ras signalling is implicated in most human neoplasia, exemplified by melanoma. Whereas
Raf activation occurs almost ubiquitously in benign and malignant melanocytic neoplasms, implying an
involvement in tumour initiation, phosphoinositide 3-kinase (PI3K) activation occurs predominantly in
malignant neoplasms, implying an involvement in malignant progression. Here, we dissect the
contributions of these two pathways to tumourigenesis in vivo, by modulating their activities in
zebrafish melanocytes. Misexpression of oncogenic Ras (V12RAS) in founder fish induced frequent
melanoma, beginning at larval stages, with concomitant activation of Raf-Mek-Erk and PI3K-Akt
signalling. Misexpression of effector-domain mutants of V12RAS, or of various downstream effectors,
confirmed a selective role for the Raf-Mek-Erk pathway in initiating neoplasia, but highlighted the
requirement for additional Ras effector pathways for malignancy. The phenotype of animals with
germ-line transmission of V12RAS resembled familial atypical mole and melanoma (FAMM)
syndrome: melanocytes displayed hyperplasia, dysplasia, altered terminal differentiation and
spontaneously progressed to invasive melanoma. Co-expressing a dominant-interfering form of PI3K
abolished V12RAS-induced malignancy, demonstrating a direct role for PI3K signalling in the
malignant progression of melanoma in vivo, and highlighting PI3K as a promising target for melanoma
therapy.
INTRODUCTION
Cutaneous melanoma, an aggressive cancer arising from epidermal
melanocytes, is a disease with an unmet clinical need. Its incidence
in Northern Europe, North America and Australia has risen
dramatically over the last few decades, faster than any other cancer
(Cancer Research UK, 2006). In the majority of cases, the disease
is still localised at diagnosis and can be cured by surgical excision.
However, metastatic disease is largely refractory to all current forms
of therapy and affected individuals have a median survival time of
only 6 months. Approximately 20% of people diagnosed with
melanoma succumb to their disease (Cancer Research UK, 2006).
Thus, there is an urgent need to understand the molecular basis
of this disease in order to develop better treatments.
Melanoma progresses through a series of histological steps. The
first step is proliferation of cytologically normal, nested
melanocytes and subsequent senescence, resulting in a benign
naevus. The second step is more deranged growth with scattered
cytological atypia, which may occur in a pre-existing benign naevus
or, more typically, at a de novo site, generating a dysplastic naevus.
At the third step, dysplastic melanocytes proliferate and invade the
epidermis and papillary dermis, giving rise to a superficially
spreading lesion with continuous atypia, commonly referred to as
a radial-growth phase (RGP) melanoma, but also as melanoma in
situ. At the fourth step, vertical-growth phase (VGP) melanoma,
malignant cells acquire the ability to invade the dermis and
subcutaneous tissues, resulting in an expansile nodule. At the fifth
and final step, metastatic melanoma, malignant cells disseminate
through the vasculature and lymphatic system to secondary sites.
The transition from RGP to VGP is accompanied by a dramatic
deterioration in prognosis.
In common with other cancer progression models, the above
transitions are assumed to reflect a stepwise transformation of
melanocytes by the acquisition of mutations in select oncogenes
and tumour suppressor genes, a number of which have now been
identified (Haluska et al., 2006; Dahl and Guldberg, 2007).
Activating BRAF mutations (particularly the valine for glutamate
substitution at position 600) are believed to initiate the sequence
of melanocyte neoplasia, since both common naevi and
malignancies frequently (approximately 80% of cases) harbour such
mutations (Pollock et al., 2003). Clearly, BRAF mutation alone does
not trigger malignant progression. Raf serine/threonine kinases that
act in the Mek-Erk signal transduction pathway are downstream
effectors of Ras oncoproteins. Activating mutations in NRAS
(typically a lysine for glutamine substitution at position 61) occur
in 15-25% of naevi and melanomas, but never occur together with
BRAF mutations, suggesting that activation of NRAS can play an
equivalent role to BRAF activation in initiating melanocyte
neoplasia (Haluska et al., 2006; Dahl and Guldberg, 2007).
Class I phosphoinositide 3-kinases (PI3Ks) are also effectors of
Ras signalling and are activated in a significant fraction of
melanomas, largely through loss of function of the tumour
suppressor phosphatase and tensin homolog (PTEN) (Wu et al.,
2003). PTEN is a phosphatase which removes the 3 phosphate from
the secondary messenger molecule phosphatidylinositol (3,4,5)-
trisphosphate [PIP3, also known as PtdIns(3,4,5)P3], which is
generated by PI3K. Akt serine/threonine kinases that are stimulated
upon PIP3 binding are found constitutively activated in cells that
lack PTEN (Birck et al., 2000). Activated Akt promotes cell survival
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by inhibiting apoptosis (Manning and Cantley, 2007), and increased
Akt activity, which can arise through either amplification of the
gene encoding AKT3 or inactivation of PTEN, may occur in 40-
60% of melanomas (Stahl et al., 2004). Loss of function of PTEN
is not observed in naevi (Tsao et al., 2004) and is observed mostly
as a late-stage event in melanoma (more than 60% of metastatic
melanomas have PTEN inactivation, in contrast to only one-third
of primary melanomas) (Guldberg et al., 1997; Birck et al., 2000;
Whiteman et al., 2002). Similarly, AKT3 activity levels also increase
with advancing melanoma stage (Stahl et al., 2004). These findings
implicate PI3K activation in the malignant progression of
melanoma. Intriguingly, NRAS and PTEN mutations appear to be
mutually exclusive in melanoma. By contrast, BRAF and PTEN
mutations coincide frequently (Haluska et al., 2006). Thus, the
human genetic data suggest that the biochemical functions of Ras
can be partitioned in melanoma cells into a Raf-signalling arm and
a PI3K-signalling arm, with discrete functions that synergise to
induce malignancy.
Studies investigating the susceptibility of hybrids of different
Xiphophorus species to develop melanocytic neoplasms were the
first to link genetic alterations with melanoma (Gordon, 1931). Fish
and mammalian melanocytes are highly analogous; in both taxa,
melanocyte precursors (melanoblasts), which are derived from a
subset of neural crest cells that arise in the dorsum, migrate to their
final destination in the integument of the animal. The proteins
regulating melanoblast specification, proliferation, survival,
migration and subsequent differentiation to melanocytes are highly
conserved in sequence and function (Bennett and Lamoreux,
2003; Kelsh, 2004). Similarly, the biochemical changes observed in
melanoma cells in Xiphophorus reveal striking similarities with
human melanoma, including activation of Ras, Erk and PI3K
signalling modules (Meierjohann and Schartl, 2006). Notably,
expression of oncogenic BRAFV600E in zebrafish melanocytes leads
to benign melanocyte neoplasia, the first demonstration in vivo
that activation of Raf-Mek-Erk signalling is sufficient to initiate
melanocyte neoplasia. Moreover, misexpression of BRAFV600E in a
p53-deficient background resulted in progression of zebrafish
naevi to melanoma (Patton et al., 2005).
In the present study, we have generated a novel melanoma model
by targeting expression of oncogenic Ras (HRASG12V) to zebrafish
melanocytes. Unlike BRAFV600E, oncogenic Ras alone was sufficient
to induce malignancy, prompting us to explore which Ras effector
pathways are implicated in initiation and which are implicated in
malignant progression of melanocyte neoplasia. We establish that
the Raf-Mek-Erk pathway is distinct among Ras effector pathways
in being able to initiate melanocyte neoplasia and demonstrate, in
this autochthonous melanoma model, a requirement for PI3K in
promoting the malignant progression of melanocytes.
RESULTS
Zebrafish melanocytes expressing oncogenic Ras are malignantly
transformed
The pigment pattern of zebrafish larvae is largely complete by 60
hours post-fertilisation (hpf), and comprises approximately 460
post-mitotic melanocytes arrayed in four longitudinal stripes
(control, Fig. 1A) (Kelsh et al., 1996). This pattern is gradually
replaced by the adult pigment pattern during the larval-to-adult
metamorphosis [2-4 weeks post-fertilisation (wpf)], and new stripes
are added gradually as the animal grows (control, Fig. 1B) (Johnson
et al., 1995).
To generate a zebrafish model of melanoma, a promoter
fragment from the zebrafish microphthalmia-associated
transcription factor a (mitfa) gene, which has previously been
dmm.biologists.org400
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Fig. 1. Generation of a melanoma model. (A) Comparison of control (GFP)
with V12RAS G0 larvae at 10 dpf. Left panel: the arrowheads indicate the wild-
type pigment stripes (from top to bottom: dorsal, lateral, ventral, yolk sac).
Right panel: V12RAS G0 larva with aberrant clonal expansion of both
melanocytes (black pigment cells) and xanthophores (yellow pigment cells).
Lesions are superficially spreading with irregular margins. There is
accompanying invasion of the ventral fin fold (arrowhead). (B) Comparison of
control and V12RAS::GFP G0 animals at 4 wpf. Note the large superficially
spreading lesion covering most of the trunk of the V12RAS::GFP G0 fish (right
panel). Dashed lines show the plane of section in E,E’,F,F’. (C) Schematic of the
Ras transgene insert. (D) Simultaneous expression of GFP reveals the full
extent of malignant spread of melanoma cells in this 4 wpf V12RAS::GFP G0
animal. Note that melanin masks GFP expression. (D’) Magnification of the area
boxed in D reveals individual malignant melanocytes at the advancing edge of
the tumour. (E,E’,F,F’) Transverse sections of the control and V12RAS::GFP G0
animals shown in B, stained with haematoxylin and eosin (H&E). In the
sections of the control animal, note the melanocytes in their usual position
beneath the dermis (arrowheads in E and E’). By contrast, the melanocytes in
the neoplastic regions in the V12RAS-injected animal have expanded, are
multilayered (arrowheads in F’) and have spread downward into the interstitial
spaces between the muscle fascicles of the trunk (examples are circled) and
enveloped the spinal cord; in addition, they have spread upward into the
epidermis (arrow in F). Bars, 200 μm (A); 0.2 cm (B,D); 20 μm (D’); 100 μm
(E,E’,F,F’).
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reported to direct exogenous protein expression to cells of the
melanocyte lineage (Dorsky et al., 2000) and has been used to
misexpress BRAFV600E and generate zebrafish naevi (Patton et al.,
2005), was coupled to a cDNA encoding human HRAS with an
oncogenic valine for glycine substitution at position 12
(HRASG12V, hereafter referred to as V12RAS). Whereas in humans
NRAS is more frequently mutated in melanoma than HRAS,
zebrafish Ras paralogues are equidistantly related to mammalian
HRAS and NRAS (see supplementary material Fig. S1). Moreover,
oncogenic HRAS and NRAS were shown to be equally effective
in inducing melanoma in a reconstituted human skin model
(Chudnovsky et al., 2005). Furthermore, transgenic expression of
oncogenic HRAS (Chin et al., 1997; Broome Powell et al., 1999)
or NRAS (Ackermann et al., 2005) in mouse melanocytes induces
melanoma formation. To aid identification of transgenic cells and
organisms, the transgene plasmid used to induce melanoma in
our model also contained a second expression cassette comprising
green fluorescent protein (GFP) cDNA coupled to the mitfa
promoter fragment (Fig. 1C).
From 96 hpf onward, and in contrast to control animals injected
with only a GFP-encoding plasmid, mosaic G0 animals injected with
the V12RAS plasmid developed one or more clones of ectopic
melanocytes that continued to expand radially, generating
superficial spreading lesions with irregular borders that were
frequently associated with scattered melanocytes [a representative
lesion at 10 days post-fertilisation (dpf) is shown in Fig. 1A and
another at 4 wpf in Fig. 1B]. Ectopic patches of xanthophores were
also observed, consistent with Mitf being expressed in a subset of
xanthoblasts (xanthophore precursors) (Parichy et al., 2000). Within
a few weeks, a fraction of these lesions progressed to give expansile
nodules (arrowhead in Fig. 1D). Overall, we determined that, by
12 weeks, 60% of transgenic animals possessed one or more
superficial lesion, whereas 30% possessed nodules (n>200 injected
animals); tumour nodules arose most frequently on the fins, but
could also arise on the flanks and, occasionally, the uvea (see Fig.
4A). By examining malignant cells in living hosts by exploiting their
fluorescence, we consistently (n=12/12) observed an advancing
front of superficially located tumour cells that were GFP-positive
but unpigmented. This advancing front was continuous, albeit with
an irregular margin, and we observed numerous pseudopodial
extensions (Fig. 1D’). Fluorescence time-lapse videos of up to 8
hours did not reveal significant translocation of tumour cells,
although frequent retraction and extension of pseudopodia were
observed (data not shown). These types of dynamic changes in cell
shape are associated typically with a migratory and invasive cellular
behaviour (Yamaguchi et al., 2005).
Fish integument consists of a stratified squamous epidermis
and an underlying dermis, itself comprising an outer looser
network of connective tissue (the stratum spongiosum) and an
inner collagen-rich layer (the stratum compactum) (Ostrander,
2000). In teleost (ray-finned) fish, the trunk epidermis is layered
over mineralised collagenous plates called elasmoid scales, which
overlap in zebrafish. Squamation begins at around day 20 or when
fish reach a standard length of 8 mm (Sire et al., 1997). The
disposition of pigment cells in the zebrafish integument has been
detailed previously (Hirata et al., 2003; Hirata et al., 2005). The
majority of melanocytes (typified by those cells comprising the
horizontal stripes of the trunk) reside in ribbons that are four to
six cells wide and one cell thick, sandwiched between sheets of
iridiphores (metallic-appearing pigment cells) and xanthophores.
This sandwich of pigment cells is located between the stratum
compactum and the muscle layer, in a layer known as the
hypodermis (Hirata et al., 2003; Hirata et al., 2005). Occasional
pigment cells are also dispersed in the stratum spongiosum of
the dermis. This is particularly evident in the scales over the
dorsum.
Histological examination of radially expanding lesions induced
by V12RAS revealed a malignant spread of atypical melanocytes
beneath the dermis, as well as into the loose connective tissue
surrounding the muscle fascicles of the trunk musculature and,
occasionally, into the epidermis (Fig. 1E-F’). We classified these
neoplastic lesions as zebrafish RGP melanoma. This contrasts with
the presentation of benign melanocyte neoplasia induced by
oncogenic BRAF, which has been reported previously in zebrafish
(Patton et al., 2005), where hyplerplasia alone was observed,
resulting in nests of melanocytes in their correct location and with
normal morphology. Moreover, histological examination of tumour
nodules and the surrounding structures was consistent with a
classification of VGP melanoma. V12RAS-expressing tumour cells
were found to have dispersed extensively (Fig. 2A,B), infiltrating
bone, muscle and spinal chord (Fig. 2C,D), but not to have invaded
the peritoneum or to have formed visceral metastases (Fig. 2B).
The lack of metastasis to visceral organs was common to all
V12RAS-expressing animals that were examined histologically
(n=22, three sections per animal, encompassing its breadth). Similar
to human melanoma (Massi and LeBoit, 2004), zebrafish melanoma
cells within nodules most frequently displayed epithelioid
morphology, nuclear pleiomorphism with prominent nucleoli,
frequent mitotic figures, and were unpigmented, although a
significant fraction of melanin-containing dendritic cells were
typically present, leading to an overall melanotic appearance (Fig.
2E). Malignant cells were hyperproliferative as indicated by the
induction of proliferating cell nuclear antigen (PCNA) expression
(Fig. 2F).
As further confirmation that the expansile nodules were largely
comprised of melanoma cells, Schmorl histochemical staining was
performed to detect reducing substances such as melanin. This
revealed the presence of melanin throughout the malignant cells,
even in the absence of visible pigment granules (Fig. 3A).
Transmission electron microscopy (TEM) also confirmed the
existence of premelanosomes and mature melanosomes within
cancer cells (Fig. 3B). Furthermore, using immunohistochemistry,
fine granular tyrosinase expression could be detected in malignant
cells, again even in the absence of visible pigment granules (Fig.
3C). Since tyrosinase is required for the synthesis of melanin but
not pteridine or carotenoid pigment, its expression is consistent
with these cells belonging to the melanocyte lineage rather than
the xanthophore lineage. Previously, it has been demonstrated that
94% of human melanoma specimens displayed positive
immunoreactivity for tyrosinase (Hofbauer et al., 1998). We did
occasionally (<5% of cases) also observe malignant neoplasms
comprising mainly pigmented cells with spindle morphology
(supplementary material Fig. S2D,E), as well as nodules where the
predominant pigmented cell fraction contained yellow pigment
(these neoplasms perhaps arise from cells committed to the
xanthophore lineage) (data not shown).
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Only Raf-Mek-Erk activation is sufficient to initiate melanocyte
neoplasia
Zebrafish melanoma cells stained positively with anti-phosphoErk
and anti-phosphoAkt polyclonal antibodies following
immunohistochemistry (Fig. 3D and 3E, respectively). The anti-
phosphoErk antibody detects Erk1 and Erk2 [p44 and p42 mitogen-
activated protein kinase (Mapk)] when phosphorylated by Mek1
or Mek2 at threonine 202 and tyrosine 204 (these residues are
conserved in zebrafish Erk1 and Erk2) (supplementary material Fig.
S3A,B). Phosphorylation at these sites activates Erk (Payne et al.,
1991). Thus, positive staining with this reagent indicated that
V12RAS could efficiently activate the zebrafish Raf-Mek-Erk
signalling pathway. The anti-phosphoAkt antibody detects Akt1
that is phosphorylated at serine 473, and Akt2 and Akt3 that are
phosphorylated at the equivalent sites (these residues are conserved
in zebrafish Akt) (supplementary material Fig. S3C).
Phosphorylation at these sites (in combination with
phosphorylation at threonine 308 of Akt1, or its equivalent in Akt2
or Akt3) activates Akt (Alessi et al., 1996). Thus, again, positive
staining with this reagent indicated that V12RAS could efficiently
activate zebrafish PI3K-Akt signalling. Immunoblotting and
immunocytochemistry performed on insulin-like growth factor 1
(IGF-1)-treated zebrafish fibroblasts (AB9) also demonstrated the
suitability of the above-mentioned antibodies in detecting activated
zebrafish Erk and Akt (supplementary material Fig. S3D).
dmm.biologists.org402
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Fig. 2. Histological analysis of a representative expansile melanotic
nodule. (A) H&E staining of a sagittal section showing malignant melanocytes
invading the anal fin and the surrounding trunk muscle (dashed oval) but not
the abdominal cavity. Inset: photograph of the fish before sectioning. The
dashed box depicts the region included in the section.
(B) Immunofluorescence reveals a continuous track of V12RAS-expressing cells
spanning the region between the ventral fin and the dorsal side of the animal.
(C-E) Magnifications of the region within the dashed oval in A, revealing
extensive infiltration of the trunk muscle (C) and spinal column (D). Tumour
cells were typically unpigmented with nuclear pleiomorphism and epithelioid
morphology, intermingled with some highly pigmented dendritic cells (mel)
(E). The asterisk in D marks a nest of melanoma cells. (F) Malignant cells
express the proliferation marker PCNA: nuclei are stained blue (DAPI) and
PCNA-expressing cells are stained red (Cy3). The inset shows the continuously
proliferating intestinal crypts, stained positive for PCNA (control). Bars, 0.25 cm
(A,B); 0.5 cm (inset in A); 50 μm (C,D), 20 μm (E,F,inset in F). Abbreviations: bv,
blood vessel; int, intestine; mel, melanocyte; nr, nerve root; s.bl, swim bladder;
ver, vertebra.
Fig. 3. V12RAS activates the Raf-Mek-Erk and PI3K-Akt pathways.
(A) Schmorl cytochemical staining of melanoma cells. Blue-green granules of
insoluble Prussian Blue reveal the presence of melanin. (B) Electron
micrograph of a section from a tumour nodule reveals highly electron-dense
melanosomes and premelanosomes (see inset for higher magnification)
within tumour cells. The boxed area indicates the area magnified in the inset.
(C-F) Immunohistochemistry reveals melanoma cells that are positive (brown
stain) for tyrosinase (C), phosphoErk (D) and phosphoAkt (E) in a V12RAS-
induced melanoma. D and E indicate activation of the Raf-Mek-Erk and PI3K-
Akt pathways, respectively. (F) Control section that was not incubated with the
primary antibody (negative control). Stainings are representative of sections
from four animals. Bars, 20 μm (A); 10 μm (B); 500 nm (inset in B); 25 μm (C-F).
Abbreviations: mel, melanocyte; mls, melanosomes; pmls, premelanosomes.
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To address which Ras effector pathways were sufficient for
initiating melanocyte neoplasia, we adopted two approaches: in the
first, V12RAS effector-domain mutants were substituted for
V12RAS; in the second, deregulated versions of Ras effector
molecules were substituted for V12RAS. A point mutation in the
effector domain of Ras can disrupt its interaction with a subset of
effectors (Rodriguez-Viciana et al., 1997). In this study, we used
V12RAST35S that retains signalling through Raf but is compromised
in signalling through, among other effectors, PI3K; V12RASY40C
that retains signalling through the p110 catalytic subunit of PI3K
but is compromised in signalling through, among other effectors,
Raf; and V12RASE37G that is compromised in signalling through
both Raf and PI3K but retains signalling through Ral guanine
nucleotide dissociation stimulators (RalGDSs), which are another
class of Ras effectors. Again, transgene vectors were tagged with a
GFP expression cassette that allowed us to confirm comparable
uptake of the constructs (not shown). Expression of the Ras
effector-domain dual cassettes was confirmed by transient
expression in cultured cells and by immunoblotting (supplementary
material Fig. S4A-C). Of these three effector-domain mutants,
V12RAST35S induced melanocyte neoplasia (11% at 12 wpf, n=81)
(Fig. 4B), whereas V12RASY40C (Fig. 4C) and V12RASE37G (not
shown) did not (see Table 1 for neoplasia incidences per transgenic
construct). All lesions were, however, benign naevi that took in
excess of 8 weeks to materialise and whose size was limited over
the life of the organism (progression to melanoma was not observed
in >24 months). Histologically, lesions were indistinguishable from
those induced by BRAFV600E (Patton et al., 2005), comprising only
hyperplastic melanocytes (supplementary material Fig. S2B). The
finding that lesions were obtained with V12RAST35S alone suggests
that only Raf-Mek-Erk signalling is sufficient to initiate neoplasia.
Furthermore, the absence of any lesions with V12RASY40C or
V12RASE37G (which fail to activate Raf) is consistent with Raf-Mek-
Erk signalling being necessary for melanocyte neoplasia. Finally,
the finding that benign lesions only were obtained with V12RAST35S
with impaired PI3K signalling ability, whereas V12RAS with a wild-
type effector domain induced malignancy, is consistent with a role
for PI3K in the malignant progression of melanocytic neoplasms.
To further validate the selective role of Raf-Mek-Erk signalling
in initiating melanocyte neoplasia, we also constructed transgenes
coupling the mitfa promoter fragment with cDNA encoding human
BRAFV600E (this oncogenic mutation introduces a phosphomimetic
conformational change in the activation domain of BRAF, resulting
in a large increase in basal kinase activity) (Wan et al., 2004);
p110αCAAX (p110α is rendered constitutively active by membrane
tethering through fusion to an exogenous CAAX motif )
(Rodriguez-Viciana et al., 1997); AktDD (Akt1, in which two
regulatory amino acids threonine 308 and serine 473 have been
replaced with phosphomimetic aspartate residues, rendering the
kinase constitutively active) (Govindarajan et al., 2007); RlfCAAX
(a constitutively active membrane-tethered form of the RalGDS Rlf,
also known as Rgl2, which also lacks its auto-inhibitory Ras-
association domain) (Wolthuis et al., 1997); or N-terminally
truncated (C1199)Tiam1 (a markedly stabilised version of Tiam1)
(Habets et al., 1994), a Rac guanine nucleotide exchange factor that
is also a Ras-interacting protein and downstream effector (Lambert
et al., 2002). The proteins encoded by these cDNAs are highly
conserved in zebrafish (supplementary material Fig. S5A-E).
Likewise, the zebrafish Ral and Rac isoforms, which interact with
Rlf and Tiam1, respectively, are >95% identical to their mammalian
counterparts (supplementary material Fig. S5F,G).
Successful cloning of all the above constructs was verified by
transient transfection and immunoblotting (supplementary
material Fig. S4D-F). Each of the above constructs was injected
into zebrafish zygotes. GFP expression from an accompanying
expression cassette confirmed equal uptake of all transgene
constructs (not shown). Only BRAFV600E induced naevi (Fig. 4D),
with an incidence (15%, n=87) and latency that were comparable
to those observed by V12RAST35S (see also Table 1), as described
previously (Patton et al., 2005). Histological examination of
BRAFV600E-induced neoplasms confirmed their benign status
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Table 1. Neoplasia incidence in G0 animals
Transgenic G0 animals Lesions at 12 wpf
V12RAS::GFP 90% (n=251)*
V12RAST35S::GFP 11% (n=81)†
V12RASY40C::GFP 0 (n=93)
V12RASE37G::GFP 0 (n=78)
BRAFV600E::GFP 15% (n=87)†
p110 CAAX::GFP 0 (n=126)
RlfCAAX::GFP 0 (n=122)
(C1199)Tiam1::GFP 0 (n=87)
BRAFV600E::p110 CAAX 14% (n=84)†
AktDD::GFP 0 (n=121)
BRAFV600E::AktDD 0 (n=167)
Table 1 summarises the incidence of neoplasia for each transgenic construct at 12
weeks after injection. *Both superficial spreading lesions and expansile nodules.
†Benign naevi.
Fig. 4. Raf-Mek-Erk selectively initiates melanocyte neoplasia. (A) G0
animals expressing V12RAS often exhibit multiple lesions along the trunk, fins
and, less frequently, in the uvea (arrowheads). (B) By comparison, the effector-
domain mutant V12RAST35S (which signals through Raf) induced formation of
benign naevi only (arrowhead). (C) V12RASY40C (an effector-domain mutant
that signals through PI3K) did not induce neoplasia. (D) In agreement with B,
expression of BRAFV600E alone in melanocytes was sufficient to induce benign
neoplasias only (arrowhead). The fish depicted are representative for each
construct. Bars, 0.5 cm (A); 1 cm (B-D).
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(supplementary material Fig. S2C). Again, these data support the
above inference that, of the Ras effector pathways targeted, only
Raf-Mek-Erk signalling is sufficient to initiate neoplasia in an
otherwise wild-type genetic background, but that alone this
pathway does not induce malignancy.
Efficient melanomagenesis requires an intact PI3K-Akt signalling
pathway
The relative inefficiency of V12RAST35S and BRAFV600E at inducing
neoplasia (11% and 15%, respectively) when compared with
V12RAS (90%), suggested that additional ‘hits’ (genetic or
epigenetic) other than activation of Raf signalling are required for
initiation of melanoma. Together, activation of the PI3K-Akt
signalling module by V12RAS and its mutational targeting in
human melanoma prompted us to examine whether PI3K-Akt
signalling is required for efficient melanomagenesis by oncogenic
Ras. To address this, we co-expressed V12RAS with an inhibitor
of the PI3K pathway, a mutant form of the PI3K regulatory domain
p85 (referred to elsewhere, and also herein, as Δp85) in which a 35
amino acid in-frame deletion in the interSH2 domain deletes the
p110 interaction domain (Rodriguez-Viciana et al., 1997)
(supplementary material Fig. S4G; Fig. S5H). Expression of Δp85
alone produced no overt effect on pigmentation in G0 animals (data
not shown). G0 animals expressing V12RAS alone or co-expressing
V12RAS with Δp85 (V12RAS::Δp85) were followed until 12 wpf
and were scored positive if they displayed one or more melanin-
pigmented neoplasms, either superficial or nodular. Co-expression
of Δp85 with V12RAS (Fig. 5A; supplementary material Fig. S4G)
significantly impaired V12RAS-induced tumourigenicity: we
observed an 80% reduction in neoplasia-positive animals co-
expressing V12RAS and Δp85 compared with those expressing
V12RAS alone (Fig. 5B) (a typical lesion induced by the RAS::Δp85
construct is shown in Fig. 5C). Furthermore, nodular lesions were
only observed in animals expressing V12RAS alone. This result
suggests that stimulation of the PI3K-signalling module is required
for efficient initiation of neoplastic transformation by V12RAS.
Indeed, the frequency of neoplasia induced by the V12RAS::Δp85
construct was comparable to the frequency induced by V12RAST35S
and BRAFV600E, consistent with the above finding that Raf-Mek-
Erk signalling is inefficient at inducing neoplasia.
Raf-Mek-Erk and PI3K-Akt signalling fail to synergise to induce
malignancy
From the above data, we inferred that although an input from BRaf
is essential for neoplasia, it is not sufficient for malignancy. Since
expression of oncogenic Ras alone can induce malignancy, we
hypothesised that a combination of Ras effectors, which should
include BRaf, is required to reconstitute the full effect of V12RAS.
For reasons stated above, co-activation of the PI3K-Akt pathway
seemed the most obvious candidate. To test this, we constructed
plasmids allowing co-expression of BRAFV600E with either
p110αCAAX or AktDD (see supplementary material Fig. S4D and
S4F, respectively). Neither of these constructs could induce
melanoma (see Table 1). Rather, with co-expression of
p110αCAAX, we observed benign naevi at a similar frequency and
latency as for BRAF alone (14%, n=84) (Fig. 5D), whereas co-
expression of AktDD resulted in no apparent lesions (n=167) (Table
1). Co-expression of RlfCAAX or (C1199)Tiam1 also failed to
augment the tumourigenic effect of BRAFV600E (data not shown).
In all cases, a benign histology was confirmed (data not shown).
Thus, combined Raf-Mek-Erk and PI3K-Akt-signalling was not
sufficient to induce malignancy, suggesting that, in addition to
activation of these two pathways, one or more additional V12RAS-
dependent signals are required to reconstitute the full effect of
V12RAS.
F1 animals demonstrate the role of PI3K signalling in the benign-
to-malignant transition
G0 animals display mosaic expression of transgenic constructs,
which results in phenotypic variation both between transgenic
clones of cells within an organism, as well as inter-individual
variation. To generate transgenic animals with a uniform phenotype
and, thus, to simplify analysis, G0 fish were used to found stable
transgenic lines. F1 transgenic animals expressing V12RAS in all
melanocytes (from four independent lines) had a common
phenotype that entailed both hyperplasia and dysplasia, resulting
in complete loss of the stripe pattern over the body owing to random
assortment of pigment cells (compare the wild-type fish in Fig. 6A
with the V12RAS F1 fish in Fig. 6B). Frequent progression to
nodular melanoma was observed in the fish expressing V12RAS
(37% of animals had one or more nodules by 16 weeks)
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Fig. 5. Disruption of the PI3K-Akt signalling pathway
significantly impairs the transforming ability of V12RAS.
(A) Schematic showing the dual expression cassette where
V12RAS and Δp85 are co-expressed. (B) Induction of neoplasia
is compromised significantly in the V12RAS::Δp85-expressing
animals compared with in animals expressing only V12RAS
(see Fig. 4A). The asterisk indicates statistical significance
(P<0.05) using the Chi-squared test. (C) In a minority of G0 fish,
co-expression of V12RAS and Δp85 resulted in melanocyte
naevi (white arrowheads). (D) Co-expression of BRAFV600E with
p110αCAAX resulted in the formation of benign naevi
(arrowhead) without augmenting the BRAF phenotype. The
fish depicted are 12 weeks old. Bars, 1 cm.
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(supplementary material Fig. S6A). Intriguingly, the scales over the
dorsum of these animals contain almost half the number of
pigmented melanocytes when compared with wild-type scales from
the equivalent region (supplementary material Fig. S7). However,
these melanocytes were more than four times larger than
melanocytes found on wild-type scales (supplementary material
Fig. S7). In contrast to V12RAS transgenic animals, and in
agreement with a previous study (Patton et al., 2005), F1 animals
expressing human BRAFV600E (from two independent lines)
displayed only melanocytic hyperplasia (Fig. 6C), as apparent from
broader fused stripes and more populous hypertrophic, but
correctly positioned, melanocytes associated with the scales over
the dorsum (Fig. 6C; supplementary material Fig. S7). We also
generated F1 animals co-expressing V12RAS and Δp85
(V12RAS::Δp85) (three independent lines), all with a consistent
phenotype [semi-quantitative reverse transcriptase (RT)-PCR was
used to confirm Δp85 expression] (supplementary material Fig.
S6C). These animals also displayed an overall benign phenotype
that was analogous to the BRAFV600E-expressing line (Fig. 6D),
retaining melanocyte hyperplasia but, unlike the lines expressing
V12RAS alone, no marked dysplasia. Thus, animals co-expressing
V12RAS and Δp85 possessed broader fused stripes (although
interstripes were still apparent ventrally) and more populous,
correctly positioned melanocytes associated with the scales over
the dorsum (Fig. 6D; supplementary material Fig. S7). These
melanocytes were the most similar in size and distribution to the
wild-type melanocytes (compare scales in Fig. 6A with those in
Fig. 6D; see also supplementary material Fig. S7), further confirming
their benign nature. Neither BRAFV600E-expressing animals, nor
V12RAS::Δp85 animals developed expansile nodules (no nodules
observed in >200 animals after >15 months). However, localised
regions of progression to a pigment pattern like the one seen in
fish expressing V12RAS alone were noted in V12RAS::Δp85 animals
that, nevertheless, failed to progress to VGP melanoma.
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Fig. 6. PI3K-signalling is required for benign-to-malignant transition. The
panels illustrate representative animals with an accompanying scale from the
dorsum of wild-type zebrafish (A) and of each of the transgenic line series that
were established (B-D). (B) V12RAS::GFP animals display melanocytic
hyperplasia and dysplasia that results in total aberration of the pigment
pattern. The melanocytes associated with the dorsal scales exhibit a more
chaotic distribution compared with in other genotypes. (C) BRAFV600E animals
only display melanocytic hyperplasia where the dorsal and lateral pigment
lines are fused together; melanocytes associated with the dorsal scales are
more populous in these fish. (D) V12RAS::Δp85 animals also exhibit the
features described in C, consistent with a benign neoplastic phenotype;
however, stripes are generally less uniform. Bars, 1 cm (fish); 200 μm (scales).
Fig. 7. Evidence that attenuated PI3K signalling affects the invasiveness
of transformed cells. (A-D) H&E staining on transverse sections of 6-month-
old animals. (A) Wild type: melanocytes are situated only in the hypodermis
(arrowheads). (B) V12RAS::GFP F1: note the reduction of pigmented cells in the
hypodermis and their replacement by a hyperplastic layer of unpigmented
cells (arrows). Large pigmented stellate melanocytes have invaded the
interstitial space between the muscle fascicles (asterisks) and can also be
observed in hyperplastic areas of the epidermis covering the scale
(arrowhead). (C) BRAFV600E F1: note the thicker pigmented layer in the
hypodermis; as in wild-type animals, no melanocytes are present in the
muscle. (D) V12RAS::Δp85 F1: analogous to the benign BRAFV600E F1 animals.
(E-J) Ras-expressing cells are significantly reduced in the V12RAS::Δp85 line.
(E) Immunofluorescence on a transverse section of a V12RAS::GFP F1 animal
reveals unpigmented Ras-expressing cells (red) in the hypodermis. Ras-
transformed cells can be observed invading between the muscle fascicles
throughout the section (E and F). (G) A small nodule (vertical growth phase
melanoma) has started to form showing marked invasion of the lower skin
layers. (H-J) Ras staining on a transverse section of a V12RAS::Δp85 F1
transgenic fish reveals a thin layer of Ras-expressing cells in the hypodermis (H
and arrowheads in I) and a few sporadic Ras-transformed cells between the
muscle fascicles (arrowhead in J). Immunofluorescence stainings were
performed in parallel and the images, captured using the same settings, are
representative of sections from three animals. Bars, 50 μm (A-D); 100 μm (E,H);
20 μm (F,G,I,J). Abbreviations: ep, epidermis; de, dermis.
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These macroscopic observations gave a first indication that
attenuation of PI3K signalling had suppressed the malignant
phenotype induced by oncogenic Ras. This was subsequently
confirmed by histology. As stated above, melanocytes in wild-type
animals are located largely in the hypodermis (i.e. between the skin
dermis and muscle) (Fig. 7A). In V12RAS-expressing lines,
melanocytes had expanded in the dermis and hypodermis, and were
now accompanied by a population of unpigmented cells in the
hypodermis (Fig. 7B). Strikingly, pigmented stellate melanocytes
were also observed in the interstitial spaces between the muscle
fascicles. Occasional melanocyte invasion into epidermal layers was
also apparent (Fig. 7B). This presentation can be equated to RGP
melanoma encompassing the entire body surface. In both
BRAFV600E-expressing lines (Fig. 7C) and V12RAS::Δp85 lines (Fig.
7D), melanocytes were positioned correctly in the hypodermis.
Significantly, both the presence of stellate melanocytes in between
muscle fascicles and invasion of the epidermis were completely
absent in BRAFV600E-expressing lines (Fig. 7C) and largely absent
in V12RAS::Δp85 lines (Fig. 7D and see below). This was analysed
further using immunofluorescence to detect V12RAS expression,
revealing the full extent of invasion of oncogenic Ras-transformed
cells in animals expressing V12RAS alone compared with animals
co-expressing V12RAS and Δp85. In animals expressing V12RAS
alone, the new population of unpigmented cells generated in the
hypodermis was shown to be V12RAS positive (Fig. 7E-G).
Frequent V12RAS-positive cells were also identified between
skeletal muscle fascicles of the trunk and in the overlying dermis
(Fig. 7F,G). The presence of V12RAS-expressing cells in each of
these locations in V12RAS::Δp85 animals was generally reduced
greatly (Fig. 7H), with only a few sporadic Ras-expressing cells
observed between muscle fascicles (Fig. 7I,J).
Attenuated Akt activation in V12RAS::Δp85 animals is not
accompanied by decreased cell survival
The V12RAS::Δp85 phenotype was accompanied by reduced Akt
activation (Fig. 8A), demonstrating clearly that endogenous PI3K
signalling was compromised. Furthermore, immunoblotting
revealed equivalent expression of V12RAS in animals co-expressing
V12RAS and Δp85 compared with animals expressing V12RAS
alone, excluding the possibility that reduced V12RAS expression
was responsible for the benign phenotype (Fig. 8A).
Immunohistochemistry on transverse sections of adult animals
expressing V12RAS alone, V12RAS and Δp85, or BRAFV600E alone
revealed, in all cases, only very infrequent cells that were positive
for PCNA in the integument, although PCNA positivity was
detected readily in nodular lesions arising in F1 animals expressing
V12RAS alone (data not shown). Thus, qualitatively, melanocyte
proliferation appeared similar in all genotypes. Akt is believed to
play a significant role in suppressing oncogene-induced apoptosis
and thus promoting tumour cell survival (Manning and Cantley,
2007). However, we detected an equivalent number of cells with
TdT-mediated dUTP nick-end labelling (TUNEL), signifying
apoptosis, in the integument of animals expressing either V12RAS
alone or V12RAS and Δp85 (Fig. 8B). Thus, changes in proliferation
rates or apoptosis rates seem an unlikely cause of the reduced
malignancy observed in V12RAS::Δp85 transgenic fish.
DISCUSSION
Using transgenic zebrafish models, we have demonstrated that Raf-
Mek-Erk signalling is distinct among Ras effector pathways in being
both sufficient and necessary for initiating melanocyte neoplasia.
Both mutant BRAFV600E and the Ras effector-domain mutant
V12RAST35S, which maintains an ability to signal through Raf,
induced benign melanocyte neoplasia (Fig. 4). By contrast, Ras
effector-domain mutants that are inefficient at activating Raf
(V12RASY40C and V12RASE37G) did not induce neoplasia; nor did
misexpression of p110αCAAX, AktDD, RlfCAAX or (C1199)Tiam1
(summarised in Table 1). However, through co-expression of
V12RAS and Δp85, we identified a requirement for PI3K-signalling
in the initiation of melanoma by V12RAS (Fig. 5B). This is in
agreement with Gupta et al. who found that recombinant mice, in
which the p110α-Ras interaction was abolished, were resistant to
Ras-induced tumourigenesis (Gupta et al., 2007).
Co-expression of BRAFV600E with either p110αCAAX or AktDD
in melanocytes did not result in more malignant lesions than
expression of BRAFV600E alone (Fig. 5D). Thus, simultaneous
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Fig. 8. Attenuated PI3K-Akt signalling in animals co-expressing
V12RAS and Δp85 does not affect the survival of transformed cells.
(A) Proteins extracted from caudal fin clips of V12RAS::GFP (RAS) and
V12RAS::Δp85 (RAS Δp85) transgenic animals were analysed by western
blotting for phosphoAkt, total Akt and Mitf expression (performed in
triplicate with equivalent results). This revealed equivalent expression of
V12RAS in the V12RAS::GFP and V12RAS::Δp85 animals, but reduced
phosphoAkt in the V12RAS::Δp85 animals (total Akt levels remained
constant). Equal Mitf expression for both genotypes provided an indication
that comparable numbers of melanocytes had been lysed for protein
extraction. (B) The fluorescent TUNEL assay revealed equivalent levels of
apoptosis in the V12RAS::GFP and V12RAS::Δp85 transgenic animals. The
left panels show overlays of images captured with differential interference
contrast (DIC) microscopy and Cy3 staining (TUNEL-positive cells, red),
whereas the right panels show the same sections with both DAPI (stains
nuclei blue) and Cy3 signals displayed. The arrowheads point to apoptotic
cells. The graph shows the numbers of apoptotic cells per millimetre (mm)
of integument for the two genotypes. Error bars represent the standard
error of the mean. Statistical analysis (t-test) revealed no significant
difference. Bars, 50 μm.
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activation of Raf-Mek-Erk and PI3K-Akt signalling does not fully
reconstitute oncogenic Ras signalling. This may explain why naevi
in individuals with germ-line loss-of-function mutations in the
PTEN gene are not reported to be at increased risk of progressing
to melanoma. Both the Raf-Mek-Erk and PI3K-Akt signalling
pathways individually induce senescence in primary cells (Chen et
al., 2005; Michaloglou et al., 2005; Courtois-Cox et al., 2006), and
this effect could even be additive resulting, potentially, in the
complete suppression of neoplasia that we observed with the BRAF-
AktDD dual construct (Table 1). We propose that other Ras-induced
signalling pathways uncouple the Raf-Mek-Erk and PI3K-Akt
signalling pathways from the induction of senescence. Recombinant
mouse models have indicated essential roles for RalGDS, Tiam1
and phospholipase Cε in Ras-induced skin tumour formation
(Malliri et al., 2002; Bai et al., 2004; Gonzalez-Garcia et al., 2005),
suggesting that multiple Ras pathways synergise to elicit neoplasia.
Although F1 transgenic zebrafish expressing BRAFV600E
developed only melanocyte hyperplasia, F1 animals expressing
V12RAS displayed melanocyte hyperplasia, dysplasia and invasion
of loose connective tissue (RGP melanoma) (Fig. 6B; Fig. 7B),
progressing spontaneously to deeply invasive (VGP) melanoma
(supplementary material Fig. S6B). As such, these animals may
serve as a model for familial atypical mole and melanoma (FAMM)
syndrome (formerly dysplastic nevus syndrome), although germ-
line mutations in the genes encoding the Ras proteins have not
been linked to FAMM (Pho et al., 2006). Because PTEN
inactivation or Akt gain of function are observed mainly in
advanced melanoma (Haluska et al., 2006; Dahl and Guldberg,
2007), we tested whether deregulated PI3K signalling was required
for the malignant conversion of V12RAS-expressing melanocytes.
Again in the F1 setting, we were able to demonstrate in our
autochthonous melanoma model that PI3K signalling is required
for malignant progression, corroborating recent findings that
PTEN deficiency triggers melanoma progression in the mouse
(Dankort et al., 2009). Thus, V12RAS::Δp85 F1 zebrafish effectively
phenocopied BRAFV600E F1 zebrafish, displaying, largely, features
of benign melanocyte neoplasia (compare Fig. 6C with 6D, and
Fig. 7C with 7D). Furthermore, despite reduced Akt activity (Fig.
8A), which is linked to cell survival (Manning and Cantley, 2007),
we did not detect a difference in apoptosis rates when comparing
animals expressing V12RAS alone with animals co-expressing
V12RAS and Δp85 (Fig. 8B). Our findings, implicating PI3K in
malignant progression, are consistent with the increased PI3K
activity detected in malignant melanoma in Xiphophorus
compared with in benign pigmented neoplasms (Wellbrock et al.,
1999). Likewise, combining PTEN deficiency with mammary-
specific expression of activated ErbB2 in mice, resulted in more
malignant metastatic tumours than ErbB2 expression alone
(Dourdin et al., 2008). Furthermore, PTEN deficiency in the
intestinal mucosa of Apc mutant mice resulted in progression of
intramucosal adenoma to full-thickness adenocarcinoma (Marsh
et al., 2008).
Cells expressing V12RAS alone frequently appeared to be more
primitive than benign melanocytes (in that they were
unpigmented), and whether the increased malignancy of
melanocytes expressing V12RAS alone is a direct effect of PI3K on
motility and invasiveness, or an indirect consequence of reversion
to a more primitive melanoblast-like state (or both) merits further
investigation. A V12RAS-induced delay in differentiation might also
explain the reduced number of pigmented cells in dorsal scales of
V12RAS transgenic animals compared with wild-type animals or
animals with benign melanocyte neoplasia (supplementary material
Fig. S7). Indeed, many GFP-expressing unpigmented cells can be
observed intermingled with pigmented cells in the dorsal scales of
V12RAS transgenic animals (data not shown).
The histopathology of melanocytic malignancies generated in
zebrafish and Xiphophorus models preserve many of the
microscopic features of mouse and human frank melanoma. These
features include a variable morphology of transformed cells, with
an epithelioid morphology being observed more frequently than
spindle morphology; nuclear pleiomorphism and prominent
nucleoli; frequent mitotic figures; and variable amounts of
pigmentation (Broome Powell et al., 1999; Gimenez-Conti et al.,
2001; Massi and LeBoit, 2004; Ackermann et al., 2005). The ability
to induce tumours efficiently in G0 zebrafish allows a relatively rapid
assessment of the efficacy of a given oncogene in initiating
neoplasia. A large number of embryos can be microinjected with
transgenic constructs and analysed for tumour induction within
12 weeks. Thus G0 assays resemble in vitro transformation assays
in their expediency, but – since they involve live organisms – more
truthfully reflect sporadic tumourigenesis. The high penetrance and
rapid onset of melanoma in the V12RAS-induced melanoma
model described here combined with other advantages of using
zebrafish as a laboratory model organism (including optical clarity,
forward genetic power, and amenability to transgenesis and small
molecule treatment), promise to make this model a valuable tool
for gaining further insight into disease mechanism and for
developing new treatments.
METHODS
Reagents
HA-epitope-tagged human V12HRAS, V12HRAS effector-domain
mutants (V12RAST35S, V12RASE37G, V12RASY40C), and HA-
epitope-tagged murine (C1199)Tiam1 were all gifts from Angeliki
Malliri (Paterson Institute for Cancer Research, Manchester, UK).
Human BRAFV600E was a kind gift from Richard Marais (Institute
for Cancer Research, London, UK). HA-epitope-tagged murine
RlfCAAX was donated by Channing Der (University of North
Carolina, NC). Myc-epitope-tagged bovine p110αCAAX was
contributed by Andrew Gilmore (The University of Manchester,
Manchester, UK). HA-epitope-tagged bovine AktDD was donated
by Jack Arbiser (Emory University, Atlanta, GA). Bovine Δp85 was
a kind gift from Julian Downward (London Research Institute,
London, UK). A modified pBlueScript SK+ vector, in which the
multiple cloning site had been flanked by I-SceI meganuclease
restriction sites, was kindly donated by Jochen Wittbrodt (EMBL,
Heidelberg. Germany).
Constructs and generation of transgenic lines
A 744-base-pair DNA fragment, proximal to the translation
initiation codon of the zebrafish homologue (isoform a) of the
mammalian MITF gene, was cloned by PCR and subsequently
inserted into a pGEM-T cloning vector (Promega) (sequence
available upon request). Transgenes of interest, combining cDNAs
with the mitfa promoter, were assembled in a modified pBlueScript
vector using standard cloning techniques. To test combinations of
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Ras effectors, dual expression cassettes were assembled combining
cDNAs for two Ras effectors (e.g. BRAFV600E and p110αCAAX).
To assess the effect of antagonising PI3K, a V12RAS expression
cassette was combined with a Δp85 expression cassette. Successful
cloning of transgene constructs was verified in each case by (1)
restriction digest analysis (data not shown), (2) sequencing (data
not shown) and (3) by transient transfection of constructs into
HEK293 cells, followed by protein extraction and immunoblotting
to confirm that exogenous protein(s) were generated (see
supplementary material Fig. S4).
Transgenic animals were generated by co-injection of 1 nl of
plasmid DNA (25 ng/μl) with 10 U I-SceI meganuclease into one-
cell stage AB-strain zebrafish zygotes, using a PLI-90 picoinjector
microinjection station as described previously (Thermes et al.,
2002). Subsequently, animals were raised under standard conditions
(28.5°C ambient temperature, 14 hour-10 hour dark-light cycle, a
diet of brine shrimp and flake food) at the Biological Services
Facility at The University of Manchester. Individual G0 founders
were backcrossed to AB animals to generate stable transgenic lines.
Animals anaesthetised with MS222 (Sigma) were photographed
using either an unmounted Canon Digital Ixus 80 IS camera or an
Axiocam MR digital camera mounted on a Zeiss StereoLumar
stereodissecting microscope. Images were processed in Adobe
Photoshop or using Axiovision software. Fin tissue and scales were
also isolated from animals under general anaesthesia. All animal
procedures were subject to local ethical review and performed
under a Home Office Licence.
Histology and immunostaining
Adult fish euthanised by exposure to excess anaesthesia were fixed
in 4% paraformaldehyde (PFA), and paraffin-embedded tissue
sections (5 μm) were used for H&E staining, immunofluorescence
and immunohistochemistry. H&E staining was carried out using
standard methods (Thermo Shandon staining machine). For
immunofluorescence, the primary antibodies used were mouse
anti-Ras (1:100 dilution; BD Transduction Laboratories) and mouse
anti-PCNA (1:100 dilution; Euro-Diagnostica). The secondary
antibody was Vectastain biotinylated horse anti-pan-IgG. Following
incubation with the secondary antibody, the sections were
incubated with Cy3-labeled streptavidin (1:100 dilution; Sigma) and
mounted using Vectashield with DAPI (Vectorlabs) in order to
visualise nuclei. For immunohistochemistry, tissue sections were
stained with mouse anti-tyrosinase (1:50 dilution; Upstate 05-647),
rabbit anti-phosphoErk (1:100 dilution; Cell Signalling Technology)
and rabbit anti-phosphoAkt (1:100 dilution; Cell Signalling
Technology) antibodies, as per the manufacturer’s instructions.
Images were captured using a Zeiss Axioplan 2 compound
fluorescent microscope and Axiocam MR camera, and processed
using Axiovision software. Alternatively, sections were scanned, and
images were captured and processed using a Zeiss Mirax Scan
system with a 20 objective lens and a Marlin f14 6C camera. All
histological samples were evaluated by a clinical pathologist (Jivko
Kamarashev).
Schmorl stain
Paraffin sections of fish with neoplastic lesions were deparaffinised
in xylene and rehydrated in descending concentrations of ethanol.
The sections were incubated for 10 minutes with a working
solution comprising 0.75% ferric chloride and (freshly prepared)
0.1% potassium ferricyanide in distilled water, and washed in
distilled water. Melanin has the ability to reduce ferricyanide to
ferrocyanide, which in the presence of ferric ions forms Prussian
Blue and, therefore, cells containing melanin are stained blue.
Nuclear Fast Red was used as a counterstain (2 minutes) before
sections were dehydrated in ascending concentrations of ethanol.
Images were captured using a Zeiss Axioplan 2 compound
microscope and Axiocam MR camera, and processed using
Axiovision software.
Transmission electron microscopy
TEM was carried out in the EM facility of the Faculty of Life
Sciences at The University of Manchester. Specimen processing was
performed as described previously (Toma et al., 1999). Fish with
tumour nodules were sacrificed by excess anaesthetisation, and the
tumours were excised and immersed in a mixture of 3% PFA and
3% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4, for 2 hours
at room temperature. The specimens were then cut into small
pieces, immersed in the same fixative overnight at 4°C, and post-
fixed in 2% osmium tetraoxide for 2 hours at 0°C. The specimens
were block stained with 0.5% uranyl acetate in 50% ethanol
overnight and embedded in Epon 812 resin after dehydration in a
graded series of ethanol. Ultra-thin sections (70-80 nm) were cut
using a Reichert Jung Ultramicrotome. TEM observations were
carried out using a FEI Tecnai12 Biotwin microscope and
photographs were taken using a CCD camera (Eagle, FEI Company).
Images were acquired using an Imacon scanner and FlexColor
software.
Immunoblotting
For immunoblotting, protein was extracted from caudal fin clips
(n=5 for each genotype), resolved in 4-15% gradient SDS-
polyacrylamide gels (Biorad), transferred to PVDF membranes
(Millipore), and incubated with the following antibodies: anti-Ras
(BD Transduction Laboratories), anti-phosphoAkt (Cell Signaling
Technology), anti-total Akt (Cell Signaling Technology) and anti-
MITF (DakoCytomation). The secondary antibody was either anti-
mouse IgG or anti-rabbit IgG conjugated to horseradish peroxidase
(HRP) (Amersham Biosciences). Proteins were visualised with ECL
(enhanced chemiluminescence) plus (Amersham Biosciences), as
per the manufacturer’s guidelines. All immunoblotting procedures
were performed in triplicate and generated equivalent results.
Fluorescent (F)-TUNEL assay
Adult fish (n=3) from each of the V12RAS::GFP and V12RAS::Δp85
transgenic lines, sacrificed by excess anaesthetisation, were fixed
in 4% PFA and embedded in paraffin. Transverse sections (5 μm)
were used for the F-TUNEL assay. The assay was performed using
the ApopTag Red in situ apoptosis detection kit (Chemicon
International), as per the manufacturer’s instructions. Apoptotic
cells in the integument (i.e. superficial to the muscle) were counted
from three sections of each animal (i.e. nine sections in total for
each genotype) and the perimeter of each section was measured
using Axiovision software, in order to determine the number of
apoptotic cells per millimetre of integument. The measurements
were analysed for statistical significance using an independent
samples t-test.
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Bioinformatics
Protein sequences for human and murine Ras isoforms; human
ERK1 and ERK2; human AKT1, AKT2 and AKT3; human BRAF;
bovine p110α; bovine Akt; murine Rlf; murine Tiam1; murine RalA
and RalB; murine Rac1; and bovine p85 were used to identify
homologues in the zebrafish genome Zv7 sequence build
(http://www.ensembl.org/Danio_rerio/index.html) by performing
TBLASTN or BLASTP searches. Reciprocal best-BLAST and
synteny were used to confirm orthology. Peptide sequences were
aligned using ClustalW multiple alignment application of BioEdit
software.
Cell culture
HEK293 cells were maintained in DMEM/F12 Glutamax (GIBCO)
supplemented with 10% foetal calf serum (Lonza) and 1% penicillin-
streptomycin (Lonza). The cells were transfected with 1 μg of the
plasmid of interest using FuGene6 (Roche) transfection reagent,
as per the manufacturer’s instructions. AB9 zebrafish fibroblasts
were maintained in DMEM/F12 Glutamax supplemented with 15%
foetal calf serum (Lonza), 1% penicillin-streptomycin (Lonza) and
0.6% Fungizone (GIBCO). Cells were maintained at 28°C with 5%
CO2.
Cell culture immunoblotting
HEK293 cells
For immunoblotting, protein was extracted from transfected
HEK293 cells, on the third day after transfection, resolved in 4-
15% gradient SDS-polyacrylamide gels (Biorad), transferred to
PVDF membranes (Millipore) and incubated with the following
antibodies: anti-HA high affinity (Roche), anti-Ras (BD
Transduction Laboratories), anti-Akt (Cell Signaling Technology),
anti-Erk (Cell Signaling Technology), anti-BRAF (BD Transduction
Laboratories), anti-PI3K p110α (BD Transduction Laboratories),
anti-PI3K p85 (Upstate Biotechnology, Inc) and anti-β-actin
(Sigma). The secondary antibody was anti-rat IgG, anti-mouse IgG
or anti-rabbit IgG, all of which were conjugated to HRP (Amersham
Biosciences). Proteins were visualised with ECL plus (Amersham
Biosciences) according to the manufacturer’s guidelines. All
immunoblotting procedures were performed in triplicate and
generated equivalent results.
AB9 cells
AB9 cells were starved of serum for 24 hours before treatment with
IGF-1 (Gro-Pep) for 10 minutes at a final concentration of 100
ng/μl. Negative control cells were left untreated. Immediately after
IGF-1 treatment, the protein was extracted, resolved in 4-15%
gradient SDS-polyacrylamide gels (Biorad), transferred to PVDF
membranes (Millipore) and incubated with the following
antibodies: mouse anti-phosphoErk (Cell Signalling Technology),
rabbit anti-phosphoAkt (Cell Signalling Technology) and rabbit
anti-β-tubulin (Abcam). The secondary antibody was either anti-
rabbit IgG or anti-mouse IgG, both of which were conjugated to
HRP (Amersham Biosciences). Proteins were visualised with ECL
plus (Amersham Biosciences) according to the manufacturer’s
guidelines. All immunoblotting procedures were performed in
triplicate and generated equivalent results.
Immunocytochemistry
AB9 zebrafish fibroblasts grown on glass coverslips were starved
of serum for 24 hours before treatment with IGF-1 (Gro-Pep) for
10 minutes at a final concentration of 100 ng/μl. Negative control
cells were left untreated. Immediately after the IGF-1 treatment,
cells were fixed for 30 minutes at 4°C with 4% PFA, and stained
with mouse anti-phosphoErk (1:400 dilution; Cell Signalling
Technology) and rabbit anti-phosphoAkt (1:25 dilution; Cell
Signalling Technology) antibodies, as per the manufacturer’s
instructions. In order to reduce non-specific antibody binding, an
extra step of avidin-biotin block (Vectorlabs) was added just before
incubation with the primary antibody. Images were captured using
a Zeiss Axioplan 2 compound fluorescent microscope and Axiocam
MR camera, and processed using Axiovision software. The above
immunocytochemical stainings were performed in triplicate and
generated equivalent results.
Semi-quantitative RT-coupled PCR
Total RNA was isolated and pooled from caudal fin clips (n=3 for
each genotype) using the RNAeasy mini kit (Qiagen), and reverse
transcribed with an Omniscript reverse transcription kit (Qiagen)
to produce cDNA. cDNA was amplified through RT-PCR using
GoTaq polymerase (Promega) and primers that flank the wild-type
p85 sequence of both bovine and zebrafish p85. Primer sequences
are available upon request.
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TRANSLATIONAL IMPACT
Clinical issue
Deregulated Ras signalling is observed in the vast majority of human solid
neoplasias, exemplified by cutaneous melanoma. Mutational profiling suggests
that activation of Raf-Mek-Erk signalling downstream of Ras may be crucial for
initiating melanocyte neoplasia, whereas phosphoinositide 3-kinase (PI3K)-Akt
signalling is involved in malignant progression. These hypotheses have not yet
been fully tested in in vivo models. Treatment options for patients with
advanced (metastatic) melanoma are very limited and their prognosis remains
poor. Understanding the molecular basis of melanoma formation and
progression should identify potential targets for the development of more
effective medicines.
Results
The authors generate several transgenic zebrafish melanoma models by
expressing oncogenic Ras, attenuated versions of Ras, and activated Ras
effectors in their melanocytes. The ability of Ras and Ras effector mutants to
induce melanocyte neoplasia confirms an important role for Raf-Mek-Erk
signalling in melanoma initiation. Germline transmission of oncogenic Ras
produced fish that were covered with dysplastic melanocytes, which
frequently progress to melanoma, reminiscent of familial atypical mole and
melanoma (FAMM) syndrome seen in humans. Malignancy was abrogated in
these animals by co-expressing a PI3K inhibitor, confirming a role for PI3K in
melanoma progression. 
Implications and future directions
The authors created and characterise zebrafish models of melanoma through
disruption of Ras signalling. These fish display high penetrance and a rapid
onset of melanoma. These findings and other characteristics of zebrafish,
including optical clarity, forward genetic power, and amenability to
transgenesis and small molecule treatment, suggest the future utility of this
model in understanding and treating human cancer.
doi:10.1242/dmm.003574
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Scale melanocyte number and size measurements
Adult animals representative of the genotypes of interest (wild-type,
V12RAS::GFP, BRAFV600E and V12RAS::Δp85) were anaesthetised
with MS222 (Sigma), and scales were then removed from their
dorsum, behind the head, using fine forceps (n=6 scales for each
of three animals per genotype). The isolated scales were
photographed using a Zeiss StereoLumar stereodissecting
microscope and the obtained images were analysed using
Axiovision Automeasure software. This application enables the
measurement of areas with a specified density (in this case the
pigment in melanocytes). The results are given as pigmented areas
in μm2. The scales were then treated with 1 mg/ml epinephrine
(Sigma) for 5 minutes and photographed using the same
microscope with Axiovision sofware. Epinephrine aggregates the
melanosomes in the melanocytes and facilitates cell counting by
making individual cells distinct (Rawls and Johnson, 2001). For each
scale: (1) the melanocytes were counted and (2) the measurement
of pigmented area (as measured with Axiovision Automeasure) was
divided by the number of melanocytes on the scale, and a
measurement of μm2/melanocyte was obtained. A mean
measurement was generated for each genotype and analysed for
statistical significance using a one-way ANOVA test.
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